|
[1] Arndt K M, Muller K M, Pluckthun A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 1998, 37(37):12918-12926.
[2] Bird R E, Hardman K D, Jacobson J W, et al. Single-chain antigen-binding proteins. Science, 1988, 242(4877):423-426.
[3] Le Seyec J, Chouteau P, Cannie I, et al. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol, 1999, 73(3):2052-2057.
[4] Park S G, Jeong Y J, Lee Y Y, et al. Hepatitis B virus-neutralizing anti-pre-S1 human antibody fragments from large naive antibody phage library. Antiviral Res, 2005, 68(3):109-115.
[5] Scaglioni P P, Melegari M, Wands J R. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology, 1994, 205(1):112-120.
[6] Yamamoto M, Hayashi N, Takehara T, et al. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology, 1999, 30(1):300-307.
[7] 汤正好, 余永胜, 马会慧, 等. 非复制型腺病毒介导抗-HBC单链抗体的细胞内表达. 中华肝脏病杂志, 2006, 14(8):587-589. Tang Z H, Yu Y S, Ma H H, et al. Chin J Hepatol, 2006, 14(8):587-589.
[8] Zu Putlitz J, Lanford R E, Carlson R I, et al. Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. J Virol, 1999, 73(5):4188-4196.
[9] Lee M S, Kwon M H, Kim K H, et al. Selection of scFvs specific for HBV DNA polymerase using ribosome display. J Immunol Methods, 2004, 284(1-2):147-157.
[10] Diamantis I D, McGandy C E, Chen T J, et al. Hepatitis B X-gene expression in hepatocellular carcinoma. J Hepatol, 1992, 15(3): 400-403.
[11] Koike K, Moriya K, Iino S, et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology, 1994, 19(4): 810-819.
[12] Jin Y H, Kwon M H, Kim K, et al. An intracellular antibody can suppress tumorigenicity in hepatitis B virus X-expressing cells. Cancer Immunol Immunother, 2006, 55(5): 569-578.
[13] Blatt L M, Davis J M, Klein S B, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res, 1996, 16(7): 489-499.
[14] 刘顺爱, 浅野龙太郎, 王学, 等. 人源抗HBsAg ScFv与重组复合干扰素融合蛋白的高效表达及活性鉴定. 中国免疫学杂志, 2004, 20(9):629-632, 638. Liu S A, Ryutaro Asano, Wang X, et al. Chin J Immunol, 2004, 20(9):629-632, 638.
[15] Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology, 2003, 37(4):764-670.
[16] McCaffrey A P, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol, 2003, 21(6):639-644.
[17] Song E, Zhu P, Lee S K, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 2005, 23(6):709-717.
[18] Wen W H, Liu J Y, Qin W J, et al. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology, 2007, 46(1): 84-94.
[19] Lindgren M, Hallbrink M, Prochiantz A, et al. Cell-penetrating peptides. Trends Pharmacol Sci, 2000, 21(3):99-103.
[20] Ryu J, Han K, Park J, et al. Enhanced uptake of a heterologous protein with an HIV-1 Tat protein transduction domains (PTD) at both termini. Mol Cells, 2003, 16(3):385-391.
[21] Vives E, Richard J P, Rispal C, et al. TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci, 2003, 4(2):125-132.
[22] 孟艳玲, 温伟红, 薛茜, 等. 人抗HBsAg单链抗体/鱼精蛋白截短体融合蛋白基因的构建、表达及活性鉴定. 第四军医大学学报,2006, 26(20):1828-1831. Meng Y L, Wen W H, Xue Q, et al. Journal of the Fourth Miliary Medical University, 2006, 26(20):1828-1831.
[23] He D, Yang H, Lin Q, et al. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. Int J Biochem Cell Biol, 2005, 37(1):192-205.
[24] 薛茜, 温伟红, 孟艳玲, 等. 含Arg9的人抗HBsAg单链抗体／EGFP融合蛋白基因的构建、表达和内化作用的研究. 中国生物工程杂志, 2006, 26(7):1-6. Xue Q, Wen W H, Meng Y L, et al. China Biotechnology, 2006, 26(7):1-6.
[25] Xu J L, Davis M M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity, 2000, 13(1):37-45.
[26] Park S G, Jung Y J, Lee Y Y, et al. Improvement of neutralizing activity of human scFv antibodies against hepatitis B virus binding using CDR3 V(H) mutant library. Viral Immunol, 2006, 19(1):115-123.
[27] Forrer P, Jung S, Pluckthun A. Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins. Curr Opin Struct Biol, 1999, 9(4):514-520.
[28] Edwards B M, Barash S C, Main S H, et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol, 2003, 334(1):103-118.
[29] Baker K P, Edwards B M, Main S H, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum, 2003, 48(11):3253-3265.
[30] Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A, 1997, 94(10): 4937-4942.
[31] Hanes J, Jermutus L, Weber-Bornhauser S, et al. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci U S A, 1998, 95(24):14130-14135.
[32] He M, Taussig M J. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res, 1997, 25(24):5132-5134.
[33] Groves M, Lane S, Douthwaite J, et al. Affinity maturation of phage display antibody populations using ribosome display. J Immunol Methods, 2006, 313(1-2):129-139.
[34] Lillo A M, Sun C, Gao C, et al. A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents. Chem Biol, 2004, 11(7):897-906.
[35] Durrbach A, Angevin E, Poncet P, et al. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther, 1999, 6(6):564-571.
[36] Deng S X, Hanson E, Sanz I. In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies. Int Immunol, 2000, 12(4):415-423.
[37] Wen W H, Qin W J, Gao H, et al. An hepatitis B virus surface antigen specific single chain of variable fragment derived from a natural immune antigen binding fragment phage display library is specifically internalized by HepG2.2.15 cells. J Viral Hepat, 2007, 14(7):512-519.
[38] Huston J S, McCartney J, Tai M S, et al. Medical applications of single-chain antibodies. Int Rev Immunol, 1993, 10(2-3):195-217.
[39] Harris B. Exploiting antibody-based technologies to manage environmental pollution. Trends Biotechnol, 1999, 17(7):290-296.
[40] Proba K, Honegger A, Pluckthun A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol, 1997, 265, (2), 161-172.
[41] Glockshuber R, Schmidt T, Pluckthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry, 1992, 31(5):1270-1279.
[42] Cattaneo A, Biocca S. The selection of intracellular antibodies. Trends Biotechnol, 1999, 17(3):115-121.
[43] Visintin M, Tse E, Axelson H, et al. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci U S A, 1999, 96(21):11723-11728.
[44] Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol, 2001, 305(5):989-1010.
[45] Proba K, Honegger A, Pluckthun A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol, 1997, 265, (2), 161-172.
[46] Jung S, Honegger A, Pluckthun A. Selection for improved protein stability by phage display. J Mol Biol, 1999, 294(1):163-180.
[47] Jermutus L, Honegger A, Schwesinger F, et al. Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci U S A, 2001, 98(1):75-80.
[48] Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol, 1998, 280(1):117-127.
[49] Visintin M, Tse E, Axelson H, et al. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci U S A, 1999, 96(21):11723-11728.
|
